Furthermore, the human epidermal growth factor receptor 2 (HER2), involved in activating cell proliferation pathways such as PI3K-AKT and MEK-ERK, is found in 10 to 30% of NSCLC cases, especially in adenocarcinoma [62]. This evidence concerns the gene ERBB2 and adenocarcinoma.